A meta-analysis of seven SURPASS clinical trials in participants with T2DM showed the hazard ratios comparing tirzepatide versus controls of 0.80 (95% CI, 0.57 1.11) for 4-MACE, 0.90 (95% CI, 0.50 1.61) for cardiovascular death, and 0.80 (95% CI, 0.51 1.25) for all-cause mortality (264)
Supply Chain Considerations The global demand for retatrutide has created supply constraints
First impressions: convenience is the main selling point The biggest oh okay, I get it moment was how low-effort it is
So I desperately started throwing money at any "solution" I could find $400 on dermatologist visits where I was basically told to just "just wait it out" $250 on biotin supplements and hair vitamins that made no difference $180 on expensive shampoos promising to "stimulate growth" $300 on a laser cap that did absolutely nothing Each failure made me more desperate and more suspicious
GLP-1 drugs (also called GLP-1 agonists) are medications originally marketed to treat diabetes
#WeightManagement #Longevity #Wellness #FitnessInnovation MD | Power Plate & bioDensity Gulf & India | Longevity Science Strength Bone Mobility Recovery Performance Everyone is talking about Ozempic and Mounjaro right now
